REVB — Revelation Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Revelation Biosciences Announces 1-for-3 Reverse Stock Split Effective July 7
Brief: Revelation Biosciences, Inc. Announces Closing Of $4 Million Public Offering
Brief: Revelation Biosciences Announces Pricing Of $4 Million Public Offering
Revelation Biosciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Revelation Biosciences Inc. Q1 EPS USD -2.11
Revelation Biosciences Inc expected to post a loss of $6.88 a share - Earnings Preview
Brief: Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells
Stephens lowers PT for Addus HomeCare amid Medicaid funding uncertainity
Brief: Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients
Brief: Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Revelation Biosciences Announces 1-For-16 Reverse Stock Split
Brief: Nasdaq Grants Revelation Biosciences Continued Listing
Brief: Revelation Biosciences Says Phase 1B Study In CKD Patients To Begin Early 2025
Revelation Biosciences Inc expected to post a loss of $2.29 a share - Earnings Preview
Revelation Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Revelation Biosciences Inc. Q3 EPS USD -0.84
Brief: Revelation Biosciences Gemini Induced Statistically Significant, Dose Dependent Changes In Circulatory Il-10 At 2 Hours Post-Dose
Brief: Revelation Biosciences Inc. Q2 EPS USD -5.13
Revelation Biosciences Inc expected to post a loss of $1.80 a share - Earnings Preview